1-Cyano-5-methoxy-(1,2,3,4-tetrahydronaphthalene) | 81580-80-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 四氢化萘
• 英文名称: 1-Cyano-5-methoxy-(1,2,3,4-tetrahydronaphthalene)
• 英文别名: 5-Methoxy-1,2,3,4-tetrahydronaphthalene-1-carbonitrile
• CAS: 81580-80-5
• 化学式: C₁₂H₁₃NO
• mdl: MFCD08669455
• 分子量: 187.241
• InChiKey: ZABVBTPROSFSNH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.416
• 拓扑面积：
  33
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-Cyano-5-methoxy-(1,2,3,4-tetrahydronaphthalene) 在 aluminum (III) chloride 、 lithium aluminium tetrahydride 作用下， 以 乙醚 为溶剂， 以94%的产率得到N-<(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)methyl>amine
  参考文献：
  名称：

  铱配合物催化伯醇与丁醇的首次分子内烷基化

  摘要：

  描述了通过氢转移，伯和仲醇与腈进行的首次铱催化的分子内烷基化反应。该反应允许获得生物活性的芳基甲胺的前体。

  DOI：

  10.1002/ejoc.201200850
• 作为产物：
  描述：

  5-甲氧基-3,4-二氢-2H-1-萘酮 在 sodium tetrahydroborate 、 锂丁酯 、 对甲苯磺酸 作用下， 以 四氢呋喃 、 乙醇 、 苯 为溶剂， 反应 3.75h， 生成 1-Cyano-5-methoxy-(1,2,3,4-tetrahydronaphthalene)
  参考文献：
  名称：

  Structure−Activity Studies for a Novel Series of N-(Arylethyl)-N-(1,2,3,4-tetrahydronaphthalen-1-ylmethyl)-N-methylamines Possessing Dual 5-HT Uptake Inhibiting and α₂-Antagonistic Activities

  摘要：

  In search of an alpha(2)-antagonist/5-HT uptake inhibitor as a potential new class of antidepressant with a more rapid onset of action, compound 3 was prepared and observed to possess high affinity for the alpha(2)-receptor (K-i = 6.71 nM) and the 5-HT uptake site (20.6 nM). A series of tertiary amine analogs of 3 were synthesized and assayed for their affinity at both the alpha(2)-receptor and the 5-HT uptake site. The structure-activity relationship reveals that a variety of structural modifications to the arylethyl fragment are possible with retention of this dual activity. On the tetralin portion, 5-OMe substitution and the (R) stereochemistry at C-l are optimal with alternate substitutions producing compounds retaining high affinity for the alpha(2)-receptor but lacking affinity for the 5-HT uptake site. Data for several rigidified 5-O-alkyl analogs suggests that the favored orientation of the oxygen lone pairs may be away from the g-position of the tetralin.

  DOI：

  10.1021/jm960723m

文献信息

• Adrenergic amidines
  申请人：Abbott Laboratories

  公开号：US04634705A1

  公开（公告）日：1987-01-06

  Disclosed herein are adrenergic compounds represented by the formula ##STR1## wherein m is 0, 1 or 2; R.sub.1, R.sub.2, R.sub.3 and R.sub.7 are taken from the group consisting of hydrogen, hydroxy, loweralkyl, loweralkoxy, halo, amino, acetamido or NHSO.sub.2 R wherein R is taken from the group consisting of hydrogen or loweralkyl, provided that R.sub.1, R.sub.2, R.sub.3 and R.sub.7 cannot simultaneously be hydrogen or halo, and provided that when one of R.sub.1, R.sub.2, R.sub.3 and R.sub.7 is halo, the others cannot simultaneously be hydrogen and when two of R.sub.1, R.sub.2, R.sub.3 and R.sub.7 are halo, the other two cannot simultaneously be hydrogen and provided that R.sub.1 and R.sub.7 cannot simultaneously be methoxy each when R.sub.2 and R.sub.3 are hydrogen; R.sub.1 and R.sub.2 or R.sub.2 and R.sub.3 or R.sub.3 and R.sub.7 taken together can form a methylenedioxy or ethylenedioxy bridge; or R.sub.1 and R.sub.2 or R.sub.2 and R.sub.3 or R.sub.3 and R.sub.7 taken together with the aromatic ring can form a benzimidazole or indole bridge; and R.sub.4 and R.sub.5 are hydrogen or taken together form a closed ring of the formula ##STR2## wherein n is 1 or 2, and the combined solid and dashed line represents a single or double bond when n is 1, and R.sub.6 is taken from the group consisting of hydrogen or loweralkyl, and the pharmaceutically acceptable salts thereof.

  本公开涉及的肾上腺素类化合物由以下式表示：其中m为0、1或2；R.sub.1、R.sub.2、R.sub.3和R.sub.7取自氢、羟基、较低烷基、较低烷氧基、卤素、氨基、乙酰胺基或NHSO.sub.2 R的群，其中R取自氢或较低烷基，但要求R.sub.1、R.sub.2、R.sub.3和R.sub.7不能同时为氢或卤素，且当R.sub.1、R.sub.2、R.sub.3和R.sub.7中的一个为卤素时，其他的不能同时为氢，当R.sub.1、R.sub.2、R.sub.3和R.sub.7中有两个为卤素时，其他两个不能同时为氢，而且当R.sub.1和R.sub.7同时为甲氧基时，R.sub.2和R.sub.3为氢；R.sub.1和R.sub.2或R.sub.2和R.sub.3或R.sub.3和R.sub.7结合在一起可以形成甲二氧基或乙二氧基桥；或者R.sub.1和R.sub.2或R.sub.2和R.sub.3或R.sub.3和R.sub.7与芳香环结合在一起可以形成苯并咪唑或吲哚桥；R.sub.4和R.sub.5为氢或结合在一起形成下式的闭环：其中n为1或2，组合的实线和虚线代表单键或双键，当n为1时，R.sub.6取自氢或较低烷基，以及其药用可接受的盐。
• Inhibitors of blood platelet aggregation. Activity of some 1H-benz[de]isoquinolinecarboximidamides on the in vivo blood platelet aggregation induced by collagen
  作者：Tom Beetz、Dick G. Meuleman、Joop H. Wieringa

  DOI：10.1021/jm00348a020

  日期：1982.6

  A series of 33 1H-benz[de]isoquinolinecarboximidamides has been prepared and tested in the rat after intraperitoneal (ip) and/or oral (po) administration for their ability to inhibit the in vivo blood platelet aggregation induced by collagen. In this aggregation test, a considerable number of active compounds were found. Fourteen compounds were active when administered in [0.2 (mmol/kg)/day], five of which also exhibited significant po activity. One compound was toxic after ip administration but was found to be active after po administration without apparent toxicity. It is thought that the solubility of the drug in water is an important factor for the resorption after oral administration and, hence, for its oral activity.
• Adrenergic compounds
  申请人：ABBOTT LABORATORIES

  公开号：EP0166937B1

  公开（公告）日：1991-08-28
• US4634705A
  申请人：——

  公开号：US4634705A

  公开（公告）日：1987-01-06
• Structure−Activity Studies for a Novel Series of <i>N</i>-(Arylethyl)-<i>N</i>-(1,2,3,4-tetrahydronaphthalen-1-ylmethyl)-<i>N</i>-methylamines Possessing Dual 5-HT Uptake Inhibiting and α₂-Antagonistic Activities
  作者：Michael D. Meyer、Arthur A. Hancock、Karin Tietje、Kevin B. Sippy、Rajnandan Prasad、David M. Stout、David L. Arendsen、B. Greg Donner、William A. Carroll

  DOI：10.1021/jm960723m

  日期：1997.3.1

  In search of an alpha(2)-antagonist/5-HT uptake inhibitor as a potential new class of antidepressant with a more rapid onset of action, compound 3 was prepared and observed to possess high affinity for the alpha(2)-receptor (K-i = 6.71 nM) and the 5-HT uptake site (20.6 nM). A series of tertiary amine analogs of 3 were synthesized and assayed for their affinity at both the alpha(2)-receptor and the 5-HT uptake site. The structure-activity relationship reveals that a variety of structural modifications to the arylethyl fragment are possible with retention of this dual activity. On the tetralin portion, 5-OMe substitution and the (R) stereochemistry at C-l are optimal with alternate substitutions producing compounds retaining high affinity for the alpha(2)-receptor but lacking affinity for the 5-HT uptake site. Data for several rigidified 5-O-alkyl analogs suggests that the favored orientation of the oxygen lone pairs may be away from the g-position of the tetralin.